SCHEMBL5544690

SCHEMBL5544690

CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746 1.00
SCHEMBL7097725 1.00
Fluoride SCHEMBL73855 0.96 MEN1 (0.40) MEN1KMT2A
Iodide SCHEMBL115029 0.96 MEN1 (0.40) MEN1KMT2A
Fluoride SCHEMBL1025917 0.96 MEN1 (0.40) MEN1KMT2A
SCHEMBL319537 0.96 MEN1 (0.40) MEN1KMT2A
SCHEMBL3210291 0.96 MEN1 (0.40) MEN1KMT2A
SCHEMBL2232066 0.96 MEN1 (0.40) MEN1KMT2A
Hydrochloric Acid SCHEMBL22577541 0.96 MEN1 (0.40) MEN1KMT2A
Ammonia Solution, Strong SCHEMBL1997314 0.96 MEN1 (0.40) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240044804-A9 BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION ROCHE DIAGNOSTICS OPERATIONS, INC. 2024-02-08 US disclosed
EP-3426398-B1 BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION ROCHE DIAGNOSTICS GMBH (DE) 2024-01-24 EP disclosed
US-20230391769-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-12-07 US disclosed
WO-2023167564-A1 METHOD FOR INCREASING PRODUCTION YIELD OF ANTIBODY-DRUG CONJUGATE BY USING THIOL-REACTIVE ADDITIVE 앱티스 주식회사 2023-09-07 WO disclosed
WO-2023163536-A1 NOVEL ANTIBODY DRUG CONJUGATE 앱티스 주식회사 2023-08-31 WO disclosed
EP-4188930-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2023-06-07 EP disclosed
US-20220177885-A1 ENDOSOMAL CLEAVABLE LINKERS ALNYLAM PHARMACEUTICALS, INC. (US) 2022-06-09 US disclosed
CN-108698047-B Branched amines in electrochemiluminescence detection 豪夫迈·罗氏有限公司 2022-04-01 CN disclosed
US-20210381987-A1 BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION ROCHE DIAGNOSTICS OPERATIONS INC (US) 2021-12-09 US disclosed
US-11125695-B2 Branched-chain amines in electrochemiluminescence detection ROCHE DIAGNOSTICS OPERATIONS, INC. 2021-09-21 US disclosed
US-20070243122-A1 Process for the synthesis and methanolysis of ammonia borane and borazine PURDUE RESEARCH FOUNDATION 2007-10-18 US disclosed
US-7122565-B2 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT LLC (US) 2006-10-17 US disclosed
EP-1326853-B1 THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER LAMBERT CO (US) 2005-09-07 EP disclosed
EP-1326853-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS Warner-Lambert Company LLC (US) 2003-07-16 EP disclosed
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT COMPANY 2003-03-06 US disclosed
CN-1100788-C Peptide for vaccine of schistosomiasis UNIV BEIJING (CN) 2003-02-05 CN disclosed
WO-2002028847-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-04-11 WO disclosed
CN-1235164-A Peptide for vaccine of schistosomiasis UNIV BEIJING MEDICAL (CN) 1999-11-17 CN disclosed
US-4892873-A MUSCLE RELAXANTS, ANTIEPILEPTIC, AN XIOLYTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1990-01-09 US disclosed
US-4822787-A 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391769-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF CYP11B2, SDHA, UGT2B7 MEN1 1349/4885KMT2A 4246/4885
US-20210381987-A1 BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION BCAT2, BCAT1, MAOB MEN1 2037/4885KMT2A 2953/4885
US-20240044804-A9 BRANCHED-CHAIN AMINES IN ELECTROCHEMILUMINESCENCE DETECTION BCAT2, BCAT1, MAOB MEN1 2037/4885KMT2A 2953/4885
US-11125695-B2 Branched-chain amines in electrochemiluminescence detection BCAT2, BCAT1, MAOB MEN1 1695/4885KMT2A 2583/4885
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors PDE3A, PDE3B, PDE7A MEN1 4216/4885KMT2A 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.